United Health Products (UEEC) Q1 2025 earnings summary

Executive summary

• Focused on obtaining FDA Class III PMA for CelluSTAT hemostatic gauze, pausing commercial activities to prioritize regulatory approval and long-term strategic options.

• No revenue generated in Q1 2025 as resources were allocated to regulatory and clinical activities.

• Net loss increased significantly year-over-year due to higher stock-based compensation expenses.

• Company evaluating potential sale, merger, or commercial partnerships pending FDA approval.

Financial highlights

• Net loss for Q1 2025 was $1,531,659, compared to $451,938 in Q1 2024.

• Operating expenses rose to $1,489,216 from $425,094 year-over-year, mainly due to $1,120,125 in stock-based compensation from RSU vesting.

• No revenue reported for both Q1 2025 and Q1 2024.

• Cash on hand at March 31, 2025 was $4,914, down from $168,883 at December 31, 2024.

• Negative working capital of $1,771,186 as of March 31, 2025.

Outlook and guidance

• FDA review of PMA application is paused pending additional clinical data; timeline for approval remains uncertain.

• Company intends to finance operations through equity sales and convertible notes until revenue generation resumes.

• Exploring strategic alternatives including sale, merger, or partnerships.